RXRX - Recursion Pharmaceuticals Inc. (RXRX) Q4 2024 Earnings Call Transcript
2025-02-28 13:16:57 ET
Recursion Pharmaceuticals, Inc. (RXRX)
Q4 2024 Earnings Conference Call
February 28, 2025 08:30 AM ET
Company Participants
Chris Gibson - Co-Founder & Chief Executive Officer
Lina Nilsson - Senior Vice President & Head of Platform
Ben Taylor - Chief Financial Officer
Conference Call Participants
Presentation
Chris Gibson
Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the slides and I want to just set the stage first of all to share a little bit about the moment in time that we're in right now. Recursion is leading this field of TechBio. We're the frontier of this exciting opportunity to decode biology to change the way that drugs are discovered and developed. And I think what we're seeing in 2024 at Recursion are leading indicators of what this inevitable future may look like. And what we're going to see moving into 2025 now is a cascade of proof points that are going to make it more and more obvious to everyone about what the future of the biopharma industry looks like.
Now, to talk a little bit about how we've gotten to this place in 2024. I want to dive into some of the year-end review so to speak. And I want to kick that off by talking about our clinical data readouts. Last year, 2024 was the first time that we got to talk about efficacy in our first two clinical programs, REC-617 and REC-994. And I'll start with REC-617. This is a potential best-in-class CDK7 inhibitor for advanced solid tumors.
And during this sort of dose escalation phase of the study before we would have expected to see efficacy and in fact in monotherapy which also is an exciting opportunity for us, we typically would have expected to see efficacy with combo therapy. We saw not only reasonable safety, but we saw early signals of efficacy. We had one patient who had a reduction in their tumor that was sustained for six months or more and a number of patients who had stable disease. So this is really, really exciting and we're actually kicking off combo studies here in the very, very near term.
REC-994 was another program, one of the ones that helped originate Recursion an oral superoxide scavenger for the potential first in disease opportunity to treat symptomatic cerebral cavernous malformation. And we demonstrated robust chronic safety treating these patients for a year or more. But also in this signal-finding study, a study designed to help us identify early signals in efficacy across many different potential endpoints to design a future trial. We saw very encouraging reduction in lesion size based on the subjective MRI measure and also encouraging trends in functional improvement in the modified Rankin score in this Phase II study. So, very exciting from our perspective to get to start to turn over these cards of the earliest programs from the Recursion OS.
What's more we launched multiple additional trials including our REC-1245 trial in -- for RBM39 degradation in solid tumors. We are able to launch our familial adenomatous polyposis trial, REK-4881 and then also our C. difficile trial with REC-3964. Beyond that, we continue to advance the next generation of molecules towards the clinic or into the clinic with CTA and IND updates for multiple programs, including the IND clearance for LSD1 in small cell lung cancer, the CTA for MALT-1 and B-cell malignancies, we were able to initiate IND studies in our IPF program, REC-4209 and initiated IND-enabling studies in hypophosphatasia with our REV102 program which is part of a joint venture with Rallybio.
Even more happened on the pipeline slide. You can see some of the deliveries that we made here in green, you can see that we were delivering across this robust pipeline all throughout 2024 and early 2025 and we're excited to continue that as we move into the coming year. But it wasn't just our pipeline. It was also our platform that gave us so many of the early new indications that we're advancing. One of those I want to talk a little bit about today because, over the last couple of years, we've started talking mostly about our clinical programs and talking less about some of the early programs in the space. There's just not enough time to go into all the incredible science....
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript